The cannabis sector is thriving in 2025 with Trump considering reclassifying marijuana, boosting industry growth. Curaleaf’s stock is up 83% YTD, while Trulieve Cannabis rose by 52.66%. The medical cannabis market is projected to grow at 22.5% annually from 2025 to 2035 due to legalization and increased demand for alternative therapies.

The AdvisorShares Pure US Cannabis ETF (MSOS) is the top-performing cannabis ETF of 2025, with a gain of over 30%. It focuses on U.S. cannabis companies, particularly multi-state operators. MSOS launched in 2020, managing $712.7 million in assets and maintaining a concentrated portfolio with 26 stocks.

The ETF’s top 10 holdings account for 142.08% of assets, with Curaleaf, Green Thumb Industries, and Trulieve Cannabis among the top positions. MSOS has a management fee of 0.80% and a YTD return of +35.96%. Recent volume has increased significantly, making the fund options eligible for increased trading flexibility.

Federal momentum for cannabis rescheduling is ongoing, with potential changes from Schedule I to III driving record ETF activity. Companies like TerrAscend, Cresco Labs, and Glass House Brands are strengthening their balance sheets and strategies through financing, share repurchase programs, and operational adjustments.

TerrAscend secured a $79 million financing package, while Glass House Brands completed a preferred equity refinancing round. Verano’s president stepped down, and companies are exploring new markets and expanding retail reach. Overall, the cannabis sector is poised for further gains with policy changes and strategic business moves driving momentum.

Read more at Yahoo Finance: This Is the Top-Performing Cannabis ETF to Buy Now